A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease

被引:31
|
作者
Patchett, Stephanie [1 ]
Lv, Zongyang [2 ]
Rut, Wioletta [3 ]
Bekes, Miklos [1 ,4 ]
Drag, Marcin [3 ]
Olsen, Shaun K. [2 ]
Huang, Tony T. [1 ]
机构
[1] NYU, Dept Biochem & Mol Pharmacol, Sch Med, New York, NY 10016 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem & Struct Biol, San Antonio, TX 78229 USA
[3] Wroclaw Univ Sci & Technol, Dept Chem Biol & Bioimaging, Wyb Wyspianskiego 27, PL-50370 Wroclaw, Poland
[4] Arvinas Inc, 5 Sci Pk, New Haven, CT 06511 USA
来源
CELL REPORTS | 2021年 / 36卷 / 13期
关键词
RESPIRATORY-SYNDROME-CORONAVIRUS; RECOGNITION; DOMAIN; COV;
D O I
10.1016/j.celrep.2021.109754
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The SARS-CoV-2 papain-like protease (PLpro) is a target for antiviral drug development. It is essential for processing viral polyproteins for replication and functions in host immune evasion by cleaving ubiquitin (Ub) and ubiquitin-like protein (Ubl) conjugates. While highly conserved, SARS-CoV-2 and SARS-CoV PLpro have contrasting Ub/Ubl substrate preferences. Using a combination of structural analyses and functional assays, we identify a molecular sensor within the S1 Ub-binding site of PLpro that serves as a key determinant of substrate specificity. Variations within the S1 sensor specifically alter cleavage of Ub substrates but not of the Ubl interferon-stimulated gene 15 protein (ISG15). Significantly, a variant of concern associated with immune evasion carries a mutation in the S1 sensor that enhances PLpro activity on Ub substrates. Collectively, our data identify the S1 sensor region as a potential hotspot of variability that could alter host antiviral immune responses to newly emerging SARS-CoV-2 lineages.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating Activity of SARS-CoV Papain-Like Protease
    Ratia, Kiira
    Kilianski, Andrew
    Baez-Santos, Yahira M.
    Baker, Susan C.
    Mesecar, Andrew
    PLOS PATHOGENS, 2014, 10 (05)
  • [22] Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
    Brian C. Sanders
    Suman Pokhrel
    Audrey D. Labbe
    Irimpan I. Mathews
    Connor J. Cooper
    Russell B. Davidson
    Gwyndalyn Phillips
    Kevin L. Weiss
    Qiu Zhang
    Hugh O’Neill
    Manat Kaur
    Jurgen G. Schmidt
    Walter Reichard
    Surekha Surendranathan
    Jyothi Parvathareddy
    Lexi Phillips
    Christopher Rainville
    David E. Sterner
    Desigan Kumaran
    Babak Andi
    Gyorgy Babnigg
    Nigel W. Moriarty
    Paul D. Adams
    Andrzej Joachimiak
    Brett L. Hurst
    Suresh Kumar
    Tauseef R. Butt
    Colleen B. Jonsson
    Lori Ferrins
    Soichi Wakatsuki
    Stephanie Galanie
    Martha S. Head
    Jerry M. Parks
    Nature Communications, 14
  • [23] Inhibitory effects of senkyuchachosan on SARS-CoV-2 papain-like protease activity in vitro
    Yuka Kiba
    Takashi Tanikawa
    Tsuyoshi Hayashi
    Takami Yokogawa
    Aiko Sano
    Ryuichiro Suzuki
    Masashi Kitamura
    Journal of Natural Medicines, 2024, 78 : 784 - 791
  • [24] A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease
    Alessandra S. Rieder
    Bruna F. Deniz
    Carlos Alexandre Netto
    Angela T.S. Wyse
    Neurotoxicity Research, 2022, 40 : 1553 - 1569
  • [25] Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
    Shin, Donghyuk
    Mukherjee, Rukmini
    Grewe, Diana
    Bojkova, Denisa
    Baek, Kheewoong
    Bhattacharya, Anshu
    Schulz, Laura
    Widera, Marek
    Mehdipour, Ahmad Reza
    Tascher, Georg
    Geurink, Paul P.
    Wilhelm, Alexander
    van der Heden van Noort, Gerbrand J.
    Ovaa, Huib
    Mueller, Stefan
    Knobeloch, Klaus-Peter
    Rajalingam, Krishnaraj
    Schulman, Brenda A.
    Cinatl, Jindrich
    Hummer, Gerhard
    Ciesek, Sandra
    Dikic, Ivan
    NATURE, 2020, 587 (7835) : 657 - +
  • [26] Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2
    Shan, Hengyue
    Liu, Jianping
    Shen, Jiali
    Dai, Jialin
    Xu, Gang
    Lu, Kuankuan
    Han, Chao
    Wang, Yaru
    Xu, Xiaolong
    Tong, Yilun
    Xiang, Huaijiang
    Ai, Zhiyuan
    Zhuang, Guanglei
    Hu, Junhao
    Zhang, Zheng
    Li, Ying
    Pan, Lifeng
    Tan, Li
    CELL CHEMICAL BIOLOGY, 2021, 28 (06) : 855 - +
  • [27] Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease
    Li, Lingyu
    Ma, Liyan
    Hu, Yue
    Li, Xiaoxue
    Yu, Meng
    Shang, Hai
    Zou, Zhongmei
    PHYTOCHEMISTRY, 2022, 193
  • [28] Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
    Sanders, Brian C.
    Pokhrel, Suman
    Labbe, Audrey D.
    Mathews, Irimpan I.
    Cooper, Connor J.
    Davidson, Russell B.
    Phillips, Gwyndalyn
    Weiss, Kevin L.
    Zhang, Qiu
    O'Neill, Hugh
    Kaur, Manat
    Schmidt, Jurgen G.
    Reichard, Walter
    Surendranathan, Surekha
    Parvathareddy, Jyothi
    Phillips, Lexi
    Rainville, Christopher
    Sterner, David E.
    Kumaran, Desigan
    Andi, Babak
    Babnigg, Gyorgy
    Moriarty, Nigel W.
    Adams, Paul D.
    Joachimiak, Andrzej
    Hurst, Brett L.
    Kumar, Suresh
    Butt, Tauseef R.
    Jonsson, Colleen B.
    Ferrins, Lori
    Wakatsuki, Soichi
    Galanie, Stephanie
    Head, Martha S.
    Parks, Jerry M.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [29] Inhibitory effects of senkyuchachosan on SARS-CoV-2 papain-like protease activity in vitro
    Kiba, Yuka
    Tanikawa, Takashi
    Hayashi, Tsuyoshi
    Yokogawa, Takami
    Sano, Aiko
    Suzuki, Ryuichiro
    Kitamura, Masashi
    JOURNAL OF NATURAL MEDICINES, 2024, 78 (03) : 784 - 791
  • [30] A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease
    Rieder, Alessandra S.
    Deniz, Bruna F.
    Netto, Carlos Alexandre
    Wyse, Angela T. S.
    NEUROTOXICITY RESEARCH, 2022, 40 (05) : 1553 - 1569